BMO Starts Biotech Stocks: AMGN, HGSI, REGN, CELG at Outperform, AMLN, GILD, ARNA at Market Perform, BIIB at Underperform

BMO Capital's Jim Birchenough initiated coverage on a litany of stocks in the Biotech and Drugs sector Wednesday afternoon.

With an Outperform rating:

• Amgen (Nasdaq: AMGN) - $67 price target
  
• Human Genome (Nasdaq: HGSI) - $28 price target
  
• Celgene (Nasdaq: CELG) - $90 price target
  
• Ariad Pharma (Nasdaq: ARIA) - $18 price target
  
• Regeneron Pharma (Nasdaq: REGN) - $78 price target
  
• Rigel Pharma (Nasdaq: RIGL) - $17 price target
  
• United Therapeutics (Nasdaq: UTHR) - $54 price target
  
• Isis Pharma (Nasdaq: ISIS) - $15 price target
  
• Halozyme (Nasdaq: HALO) - $13 price target
  
• Cardiome Pharma (Nasdaq: CRME) - $11 price target

With a Market Perform rating:

• Amylin (Nasdaq: AMLN) - $12 price target
  
• Gilead Sciences (Nasdaq: GILD) - $40 price target
  
• Arena Pharma (Nasdaq: ARNA) - $1 price target
  
• Onyx Pharma (Nasdaq: ONXX) - $34 price target
  
• ZIOPHARM (Nasdaq: ZIOP) - $6 price target
  
• NPS Pharma (Nasdaq: NPSP) - $8 price target
  
• Array BioPharma (Nasdaq: ARRY) - $3 price target
  
• Synta Pharma (Nasdaq: SNTA) - $4 price target

With an Underperform rating:

• Biogen (Nasdaq: BIIB) - $74 price target
  
• Genomic Health (Nasdaq: GHDX) - $15 price target

Check out our Ratings Insider portal to get the most comprehensive and up-to-date analyst coverage on the Street.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• TD Cowen Resumes EQT Corp. (EQT) at Hold
• BMO Capital Reiterates Outperform Rating on National Health Investors (NHI)
• Infosys Technologies (INFY) PT Lowered to $18 at BMO Capital